Pentwater Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Pentwater Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400,000	Closed	-$760K	–	145
2022 Q4	$760K	Buy	+400,000	New	+$1.01M	0.01%	104
2018 Q4	–	Sell	-13,350	Closed	-$409K	–	140
2018 Q3	$409K	Sell	13,350 -1,650	-11%	-$44.5K	﹤0.01%	129
2018 Q2	$402K	Buy	+15,000	New	+$396K	﹤0.01%	110

Other funds holding AUTL

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

OAMG

Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Pentwater Capital Management's AUTL Position: Q1 2023 in Review

Pentwater Capital Management sold out of Autolus Therapeutics (AUTL) in Q1 2023, closing a stake of 400,000 shares — an estimated $760K sold.

Pentwater Capital Management first reported a position in AUTL in Q2 2018 and held it in 3 quarters. The position peaked at $760K in Q4 2022. 65 funds tracked by Wall St. Rank hold AUTL as of Q1 2023.

Pentwater Capital Management reported no remaining Autolus Therapeutics position as of Q1 2023 after selling out during the quarter.
Pentwater Capital Management sold 400,000 Autolus Therapeutics shares in Q1 2023, an estimated $760K.
Pentwater Capital Management first reported a position in Autolus Therapeutics in Q2 2018 and held it in 3 quarters.
Pentwater Capital Management's Autolus Therapeutics position peaked at $760K in Q4 2022.
65 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2023.

Based on Pentwater Capital Management's 13F filing for Q1 2023, filed 15 May 2023.